open access
Combination Therapies of Hypomethylating Agents for Elderly Patients with Acute Myeloid Leukemia
Affiliations- Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, 210029, Nanjing, China
open access
Abstract
Older patients with acute myeloid leukemia (AML) are encumbered with poor long-term outcomes due to patient and disease characteristics. Hypomethylating agents (HMAs), acting as DNA methyltransferase (DNMT) inhibitors, have been established as a new treatment option, but they have been associated with relatively low response rates (15%–20% complete remission) when administered separately for treating elderly with AML. However, appropriate combination therapies with decitabine or azacitidine have flourished. The results of randomized trials of various combinations of HMAs with chemotherapy, histone deacetylase inhibitors, monoclonal antibodies, immunomodulatory agents, kinase inhibitors, or bexarotene are summarized.
Abstract
Older patients with acute myeloid leukemia (AML) are encumbered with poor long-term outcomes due to patient and disease characteristics. Hypomethylating agents (HMAs), acting as DNA methyltransferase (DNMT) inhibitors, have been established as a new treatment option, but they have been associated with relatively low response rates (15%–20% complete remission) when administered separately for treating elderly with AML. However, appropriate combination therapies with decitabine or azacitidine have flourished. The results of randomized trials of various combinations of HMAs with chemotherapy, histone deacetylase inhibitors, monoclonal antibodies, immunomodulatory agents, kinase inhibitors, or bexarotene are summarized.
Keywords
acute myeloid leukemia; elderly; azacitidine; decitabine; combination therapies
About this articleTitle
Combination Therapies of Hypomethylating Agents for Elderly Patients with Acute Myeloid Leukemia
Journal
Issue
Pages
59-64
Published online
2018-08-30
Page views
168
Article views/downloads
157
DOI
10.2478/ahp-2018-0011
Bibliographic record
Acta Haematol Pol 2018;49(2):59-64.
Keywords
acute myeloid leukemia
elderly
azacitidine
decitabine
combination therapies
Authors
Jiayu Huang
Yun Lian
Sixuan Qian